Author Archives: Patricia Silva PhD

Saniona Reports Positive Results from a Phase 1 Study of Tesomet Tablets

Biotech company Saniona recently announced that the Phase 1 pharmacokinetic study of a new tablet therapy candidate for Prader-Willi syndrome, called Tesomet (tesofensine/metoprolol), produced promising results in healthy men. Prader-Willi syndrome (PWS) is an inherited disorder that creates feelings of constant hunger, which often leads to obesity and type 2 diabetes.

Prader-Willi Syndrome Investigational Therapy DCCR Enters Phase 3 Trial

A multicenter, Phase 3 clinical trial assessing diazoxide choline controlled-release (DCCR) for the treatment of Prader-Willi syndrome (PWS) recently was initiated, the trial’s sponsor, biopharmaceutical company Soleno Therapeutics, announced. Soleno is currently developing DCCR as a once-daily oral tablet for the treatment of PWS. The tablet is made of a…